Strapped For Cash GenSight Eyes Survival Options

French Firm Pulls Lumevoq Filing

The future of GenSight hangs in the balance following the decision to withdraw its application in Europe for Lumevoq, the company's gene therapy for Leber hereditary optic neuropathy, and worries over a rapidly diminishing cash pile.

IV2007_Ophthalmology_226242628_1200.jpg
• Source: Shutterstock

With only a couple of months of cash left in the bank, Gensight Biologics SA is weighing up its options after pulling a marketing authorization application to EU regulators for the eye disease gene therapy Lumevoq.

The French biotech originally filed Lumevoq (lenadogene nolparvovec) with the European Medicines Agency back in September 2020 to treat vision...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Sensory

More from Therapeutic Category